The Renin-Angiotensin System in Essential Hypertension

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by St George's, University of London.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
St George's, University of London
ClinicalTrials.gov Identifier:
NCT00141583
First received: August 31, 2005
Last updated: May 10, 2007
Last verified: May 2007
  Purpose

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.


Condition Intervention
Hypertension
Drug: Enalapril 20 mg bd
Drug: Candesartan 8 mg bd

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: The Renin-Angiotensin System in Essential Hypertension

Resource links provided by NLM:


Further study details as provided by St George's, University of London:

Primary Outcome Measures:
  • Change in BP
  • Change in PRA and aldosterone

Estimated Enrollment: 11
Study Start Date: April 2004
Estimated Study Completion Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Essential Hypertension
  • SBP 140-159 mmHg
  • DBP 90-99 mmHg

Exclusion Criteria:

  • Intolerance of or allergy to ACE Inhibitors or ARBS
  • Pregnant or Breastfeeding
  • Pre-menopausal women
  • Uncontrolled cardiac or renal failure
  • Diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141583

Contacts
Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 ext - tdoulton@sgul.ac.uk

Locations
United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL Recruiting
London, United Kingdom, SW17 0RE
Contact: Timothy WR Doulton, BSc MRCP    +44 208 725 3176 ext -    tdoulton@sgul.ac.uk   
Principal Investigator: Timothy WR Doulton, BSc MRCP         
Sponsors and Collaborators
St George's, University of London
Investigators
Principal Investigator: Timothy WR Doulton, BSc MRCP SGUL
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00141583     History of Changes
Other Study ID Numbers: LREC 01.87.10
Study First Received: August 31, 2005
Last Updated: May 10, 2007
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by St George's, University of London:
Renin-angiotensin system
ACE Inhibitor
Angiotensin Receptor Blocker

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Enalapril
Candesartan
Candesartan cilexetil
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers

ClinicalTrials.gov processed this record on August 28, 2014